Name: APOGEE THERAPEUTICS INC (APGE) Stock
Brand: APOGEE THERAPEUTICS INC
Rating: 7 (3 reviews)

APGE Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Zacks Investment Research - Mentions: AVAH

Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year?

a month ago - By: Apogee Therapeutics

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

a month ago - By: Apogee Therapeutics

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

a month ago - By: Apogee Therapeutics

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

a month ago - By: Apogee Therapeutics

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

2 months ago - By: Stocktwits - Mentions: SPY QQQ DIA DAL ...

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today

a month ago - By: Apogee Therapeutics

Apogee Therapeutics to Participate in Upcoming Conferences

a month ago - By: Apogee Therapeutics

Apogee Therapeutics to Participate in Upcoming Conferences

2 months ago - By: Zacks Investment Research

Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

2 months ago - By: The Motley Fool

Why Apogee Therapeutics Stock Triumphed on Thursday

2 months ago - By: Investor's Business Daily - Mentions: REGN SNY

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

2 months ago - By: Benzinga - Mentions: IVA HELE PLUG AZZ ...

Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

2 months ago - By: Benzinga - Mentions: TELO YYAI IHT DGNX ...

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

3 months ago - By: Apogee Therapeutics

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

3 months ago - By: Apogee Therapeutics

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

3 months ago - By: Apogee Therapeutics

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

3 months ago - By: Apogee Therapeutics

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

4 months ago - By: Apogee Therapeutics

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

4 months ago - By: Apogee Therapeutics

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

5 months ago - By: Yahoo Finance

Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug

5 months ago - By: Yahoo Finance - Mentions: GS EXAS

BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating

5 months ago - By: Yahoo Finance - Mentions: MTSR JPM

Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association

5 months ago - By: Yahoo Finance - Mentions: JPM

Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)

5 months ago - By: Yahoo Finance - Mentions: PEP

Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors

5 months ago - By: Yahoo Finance - Mentions: PEP RGC GFS

APOGEE THERAPEUTICS INC (APGE) Stock News

APGE Latest News, Press Relases and Analysis

Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year?

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today

Apogee Therapeutics to Participate in Upcoming Conferences

Apogee Therapeutics to Participate in Upcoming Conferences

Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Why Apogee Therapeutics Stock Triumphed on Thursday

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug

BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating

Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association

Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)

Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors

GlobalFoundries Stock Pops on AI Chip Designer Acquisition